Drug trial aims to stop Body's attack after Life-Saving transplant
NCT ID NCT06271616
Summary
This study is testing if a drug called ibrutinib can prevent chronic graft-versus-host disease (GVHD) in patients who have received a donor stem cell transplant. GVHD is a serious condition where the donor's immune cells attack the patient's body. The trial will enroll 40 adults who are 50-110 days post-transplant and have no signs of GVHD. Participants will take ibrutinib daily for up to one year to see if it safely reduces the risk of developing this complication.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHATIC SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.